The impact of cirrhosis on the efficacy and safety of entecavir for patients with chronic hepatitis B

Eur J Gastroenterol Hepatol. 2017 Nov;29(11):1314. doi: 10.1097/MEG.0000000000000948.

Authors

Rui Huang¹, Jian Wang, Xiang-An Zhao, Juan Xia, Chao Wu

Affiliation

¹ aDepartment of Infectious Diseases, Nanjing Drum Tower Hospital, Nanjing University Medical School bDepartment of Infectious Diseases, Nanjing Drum Tower Hospital, Clinical College of Nanjing Medical University cDepartment of Infectious Diseases, Nanjing Drum Tower Hospital, Clinical College of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.

PMID: 28953581
DOI: 10.1097/MEG.0000000000000948

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Antiviral Agents
DNA, Viral
Guanine* / analogs & derivatives
Hepatitis B e Antigens
Hepatitis B virus
Hepatitis B, Chronic*
Humans
Liver Cirrhosis
Treatment Outcome

Substances

Antiviral Agents
DNA, Viral
Hepatitis B e Antigens
entecavir
Guanine